ESMO 2026 oral slot for XmAb819 Phase 1 data lifts Xencor
- Xencor announced proffered paper oral presentation at ESMO 2026 for XmAb819 in advanced ccRCC.
- XmAb819 is first-in-class ENPP3 x CD3 T-cell engaging bispecific antibody.
- Announcement on July 17 drove shares up ~17% to close at $17.47.
- Builds on 2025 data showing 25% ORR and 70% disease control in target doses.
- Confirms expansion cohort results presentation in second half of 2026.
- Supports planned recommended Phase 3 dose selection in 2026 and pivotal study in 2027.
- Oral slot at major oncology conference viewed as highly positive signal by investors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.